Agomab Therapeutics (AGMB) Share-based Compensation (2024 - 2025)
Agomab Therapeutics (AGMB) posted quarterly Share-based Compensation of $16.2 million for Q4 2025, up 77.38% year-over-year from $9.1 million in Q4 2024, and up 77.38% quarter-over-quarter from $9.1 million in Q4 2024.
Agomab Therapeutics (AGMB) Share-based Compensation (2024 - 2025) Analysis & Trends
Agomab Therapeutics' Share-based Compensation history runs 2 years deep, the most recent figure standing at $16.2 million for Q4 2025.
- In Q4 2025, Share-based Compensation rose 77.38% year-over-year to $16.2 million; the TTM figure through Dec 2025 stood at $16.2 million (up 77.38% YoY), while the FY2025 annual figure was $16.2 million, up 75.13% from the prior year.
- Share-based Compensation for Q4 2025 stood at $16.2 million, up from $9.1 million in the prior quarter.
- The five-year high for Share-based Compensation was $16.2 million in Q4 2025, with the low at $9.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Agomab Therapeutics | 7.17 Mn | -250.41 Mn | - | 17.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.15 Mn |
| Dec 31, 2025 | 16.15 Mn |
| Dec 31, 2024 | 9.11 Mn |
| Dec 31, 2024 | 9.11 Mn |